Biocompatibility ISO 10993

Medical Device Biocompatibility Evaluation (ISO 10993) & Testing Guide

Updated: Jun 2025QTC Global Compliance TeamRegulatory reference content

Analyzing ISO 10993-1 biocompatibility principles, contact classification, chemical characterization, cytotoxicity, sensitization, irritation testing selection.

Key answer

Biocompatibility evaluation starts with chemical characterization (ISO 10993-18) rather than jumping to animal testing. Testing requirements are defined by tissue contact nature (surface, communicating, implant) and contact duration (limited, prolonged, permanent). The core compliance file is the Biocompatibility Evaluation Report (BER, compiled by qualified toxicologists).

Selecting Biocompatibility Tests Under ISO 10993-1

Under ISO 10993-1, test selection moves from simple in vitro assays to systemic toxicity. For most devices (e.g., skin contact), three basic assays are required.

  • Cytotoxicity (ISO 10993-5): highly sensitive in vitro screen; failures indicate unstable material chemistry
  • Irritation (ISO 10993-10): evaluating local reaction potential caused by device extractables
  • Sensitization (ISO 10993-10): assessing immune sensitization potential using GPMT

FAQ

Can Chemical Characterization waive biocompatibility testing?+

Under recent ISO 10993-1 guidelines and FDA reviews, chemical characterization (GC-MS, LC-MS, ICP-MS extractables testing) paired with toxicological risk assessment can support waiving certain animal studies for known safe materials, but cannot replace in vitro cytotoxicity.

Next steps

If this topic applies to your product, facility, or supply chain requirement, start by confirming the target market, customer-required standard, existing documents, audit history, and expected timeline.